The Phase 2 trial showed 22.8% weight loss at this dose
With guidance from doctors, you receive support during every step
If data continue to support consistent benefit in patients with renal disease, the tide may continue to shift away from first-line use of metformin, and to-ward a strategy that begins with an SGLT2i or GLP1RA
Trial dose groups help scientists compare outcomes, but they do not establish a personal dose, an approved dosage range, or a safe access pathway
Are more oral GLP-1 medications being developed
The good news is you can now get generic versions of GLP-1 agonists, and your local compounding pharmacy should have access to the generic version of Ozempic, called semaglutide